Back to search results

Mobile App for Young Women with Breast Cancer

This study is looking at how a mobile app called Mighty Pro Application might help young women with breast cancer. The app aims to reduce the stress (cancer-related distress) that often comes with a cancer diagnosis by offering social connections and educational information. You might be able to join if you are a woman between 18 and 45 years old, have any type or stage of breast cancer, and are a patient at Atrium Health Wake Forest Baptist Comprehensive Cancer Center. You would also need to have a certain level of distress, as measured by a screening tool. The study wants to see if the app can be successfully used and if it helps lower distress over 26 weeks. The current recruitment status is unclear.

Study design
This is a randomized study with two stages, planning to enroll 120 participants. It will compare the Mighty Pro Application to standard care.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The main study outcomes will be measured at 26 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07009093

Utility of a Mobile Application for Young Women With Breast Cancer

Recruiting
NAAges 18–45InterventionalSupportive care
Wake Forest University Health Sciences
~120 participants
Updated 2026-07-22 on ClinicalTrials.gov
What's tested:Mighty Pro Application

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Stage 1: Feasibility of Implementation of Mighty Pro App
Measured over 26 Weeks
+1 more outcome measured

Conditions

Breast Cancer
Cancer Distress

Explore related trials

Breast Carcinoma

Where it's being run

1 sites across 1 states
North Carolina1

Study leadership

  • Julie Fisher, MD · PRINCIPAL_INVESTIGATOR · Wake Forest University Health Sciences

Who to contact

Maggie Dzhanumova
[email protected]
704-754-3768
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Ability to understand and willingness to sign an IRB-approved informed consent
Age ≥ 18 and ≤ 45 years at the time of consent
Female
Established patient at Atrium Health Wake Forest Baptist Comprehensive Cancer Center (AHWFBCCC)
Histological confirmation of any type and stage (0-IV) of breast cancer
Screening (baseline) NCCN Distress Thermometer score ≥ 4
Access to a mobile device for trial purposes and an active email address
Ability to read and understand the English language. NOTE: The Mighty Pro Application is available in English only.
As determined by the enrolling Investigator, ability of the participant to understand and comply with study procedures for the entire length of the study

What this trial measures

  • Stage 1: Feasibility of Implementation of Mighty Pro App26 Weeks

    Binary variable indicating if at least one encounter with the application occurred for at least 80% of the weeks during the observation period. At the Participant level, the scale is either 0 (less than 80% utilization of the Mighty Pro App at least once per week during the 26-week observation period) or 1 (80% or greater utilization of the Mighty Pro App App at least once per week during the the 26-week observation period).

  • Stage 2: Efficacy of the Mighty Pro App26 Weeks

    Binary variable indicating if at least a 2-point improvement was achieved from baseline to 26 weeks. At the Participant level, the scale is either 0 (the study participant did not achieve at least a 2-point improvement from baseline to 26 weeks on the distress scale) or 1 (the study participant did achieve at least a 2-point improvement from baseline to 26 weeks on the distress scale). The distress scale ranges from 0 (no distress) to 10 (extreme distress).